Glioma Response to IDH Inhibition: Real-World Experience

Clin Cancer Res. 2023 Dec 1;29(23):4709-4710. doi: 10.1158/1078-0432.CCR-23-2164.

Abstract

Treatment of IDH-mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. Isocitrate dehydrogenase inhibition has a therapeutic benefit in patients with these tumors. See related article by Kamson et al., p. 4863.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / pathology
  • Glioma* / drug therapy
  • Glioma* / genetics
  • Glioma* / pathology
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Magnetic Resonance Imaging
  • Mutation

Substances

  • Isocitrate Dehydrogenase